SINOPHARM TECH (Sinopharm Tech Holdings Limited) released audited results for the financial year ended 30 June 2026.
Revenue and Earnings • Group revenue fell 25.7% year-on-year to HK$45.58 million, driven by weaker demand in the pharmaceutical supply-chain business. • Gross profit dropped 54.8% to HK$6.42 million, with margin contracting to 14% from 23%. • Loss attributable to shareholders widened to HK$9.14 million (FY 2025: HK$0.87 million loss). Total comprehensive loss reached HK$12.19 million. • Basic and diluted loss per share increased to 1.97 HK cents (FY 2025: 0.19 HK cents).
Segment Performance • Supply-chain services generated HK$45.58 million revenue, down 25.7%. • Internet Plus solution services and personal protective equipment businesses recorded no revenue during the year.
Balance Sheet and Liquidity • Cash and bank balances stood at HK$5.62 million (30 June 2025: HK$6.95 million). • Net current liabilities were HK$34.42 million; net liabilities totalled HK$48.88 million. • Gearing ratio (interest-bearing borrowings/total assets) rose to 75.8% from 9%, reflecting a smaller asset base. • No capital commitments, pledged assets or contingent liabilities were reported.
Capital and Financing Actions • In November 2024 the company issued 300.00 million ordinary shares and 1.48 billion non-voting convertible preference shares to settle shareholder loans and convertible bonds totalling HK$123.25 million. • Annual preferred distributions on the preference shares due November 2025 and 2026 (HK$7.40 million each) have been deferred to 31 December 2027. • No dividend was declared for FY 2026.
Going-Concern Note • Auditors highlighted material uncertainty as the Group recorded net liabilities and net current liabilities; management is relying on shareholder undertakings, cost controls and prospective financing to support ongoing operations.
Subsequent Events • On 17 August 2026 key shareholders provided 18-month undertakings not to demand repayment of amounts owed. • The company disclosed that public float fell below 25% in January 2026 and is working to restore compliance.
Outlook Management will focus on AI-driven supply-chain efficiencies, stricter cost control and policy-aligned growth initiatives in healthcare and “AI+” services to support long-term sustainability.